TAC1 and autoimmune thrombocytopenic purpura: Regarding interventions that target reducing pressure within the intrathecal space, Leonard and colleagues conducted a line of promising, novel research that highlighted potential pharmacological targets for reducing neurogenic inflammation (substance P) and reducing CSF secretion and/or accumulation (by targeting aquaporin water channels) to reduce ITP.32